JPH11507827A - F型ボツリヌス毒素およびその用途 - Google Patents
F型ボツリヌス毒素およびその用途Info
- Publication number
- JPH11507827A JPH11507827A JP9502798A JP50279897A JPH11507827A JP H11507827 A JPH11507827 A JP H11507827A JP 9502798 A JP9502798 A JP 9502798A JP 50279897 A JP50279897 A JP 50279897A JP H11507827 A JPH11507827 A JP H11507827A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion protein
- composition
- botulinum toxin
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010069038 botulinum toxin type F Proteins 0.000 title claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 58
- 229920001184 polypeptide Polymers 0.000 claims abstract description 56
- 239000012634 fragment Substances 0.000 claims abstract description 45
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 41
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 41
- 231100000765 toxin Toxicity 0.000 claims abstract description 37
- 239000003053 toxin Substances 0.000 claims abstract description 37
- 108700012359 toxins Proteins 0.000 claims abstract description 37
- 238000000746 purification Methods 0.000 claims abstract description 21
- 230000007888 toxin activity Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 108030001720 Bontoxilysin Proteins 0.000 claims description 56
- 229960005486 vaccine Drugs 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 229940053031 botulinum toxin Drugs 0.000 claims description 16
- 230000036039 immunity Effects 0.000 claims description 14
- 230000001681 protective effect Effects 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 12
- 238000001042 affinity chromatography Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 6
- 101710117520 Botulinum neurotoxin type F Proteins 0.000 claims description 5
- 108020004511 Recombinant DNA Proteins 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 241000193155 Clostridium botulinum Species 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002581 neurotoxin Substances 0.000 description 5
- 231100000618 neurotoxin Toxicity 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 108700005078 Synthetic Genes Proteins 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 108010055044 Tetanus Toxin Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 3
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241001112695 Clostridiales Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- ITFICYZHWXDVMU-IPTZIORSSA-N (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-amino-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]pentanedioic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)O)N ITFICYZHWXDVMU-IPTZIORSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000283907 Tragelaphus oryx Species 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001672648 Vieira Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ボツリヌス毒素活性を有さず、そしてトキソイドを有さないポリペプチドで あって、F型ボツリヌス毒素への保護免疫性を誘導する、ポリペプチド。 2.ポリペプチドであって: (a)ボツリヌス毒素活性を有さないこと、 (b)トキソイドを有さないこと、および (c)哺乳動物において、F型ボツリヌス毒素に対して保護的である免疫学的応 答を誘発し得ること を特徴とする、ポリペプチド。 3.F型ボツリヌス神経毒素の重鎖のフラグメントまたは誘導体を含む、請求項 1または2に記載のポリペプチド。 4.前記フラグメントまたは前記誘導体が600までのアミノ酸長である、請求項 3に記載のポリペプチド。 5.前記フラグメントが: (a)F型ボツリヌス毒素のアミノ酸848〜1278、 (b)F型ボツリヌス毒素のアミノ酸848〜991、 (c)F型ボツリヌス毒素のアミノ酸992〜1135、および (d)F型ボツリヌス毒素のアミノ酸1136〜1278 から選択される、請求項3または4に記載のポリペプチド。 6.前記誘導体が、請求項5に記載の(a)〜(d)の任意のフラグメントの二量 体を含む、請求項3または4に記載のポリペプチド。 7.ワクチンの製造に用いるポリペプチド組成物であって: (1)毒素活性を有さず、そして哺乳動物においてボツリヌス毒素に対して保護 免疫性を誘導し得るポリペプチド;および (2)該組成物の精製を容易にするかまたは向上させるために適合されたポリペ プチド を含む、ポリペプチド組成物。 8.前記組成物が(1)と(2)との融合タンパク質を含む、請求項7に記載のポ リペプチド組成物。 9.請求項7または8に記載のポリペプチド組成物であって: (1)請求項1〜6のいずれかに記載のポリペプチド;および (2)クロマトグラフィーカラムに結合するように適合されたポリペプチドを含 む、ポリペプチド組成物。 10.アフィニティークロマトグラフィーカラムに結合するように適合されたポ リペプチドを含む、請求項7〜9のいずれかに記載のポリペプチド組成物。 11.請求項8に記載のポリペプチド組成物であって: (a)F型ボツリヌス神経毒素のアミノ酸848〜1278と (b)精製部分 との融合タンパク質を含む、ポリペプチド組成物。 12.薬学的に受容可能なキャリア、および請求項1〜6のいずれかに記載のポ リペプチドまたは請求項7〜11のいずれかに記載のポリペプチド組成物を含む 、ワクチン。 13.請求項1〜6のいずれかに記載のポリペプチドまたは請求項7〜11のい ずれかに記載のポリペプチド組成物をコードする、組み換えDNA。 14.請求項1〜6のいずれかに記載のポリペプチドまたは請求項7〜11のい ずれかに記載のポリペプチド組成物を製造する方法であって: (a)融合タンパク質をコードするDNAを宿主細胞中で発現させる工程であって、 該タンパク質が(i)F型ボツリヌス毒素のフラグメントまたは誘導体と(ii) クロマトグラフィーカラムに結合するように適合された部分との融合物である、 工程、 (b)該宿主細胞から、該融合タンパク質を含む抽出物を得る工程、および (c)クロマトグラフィーカラムを用いて該融合タンパク質を精製する工程を包 含する、方法。 15.前記クロマトグラフィーカラムがアフィニティークロマトグラフィーカラ ムであり、そして前記融合タンパク質が基質での溶離により該カラムから除去さ れる、請求項14に記載の方法。 16.前記融合タンパク質を解離する工程、および前記毒素フラグメントまたは 誘導体を保持する工程をさらに含む、請求項14または15に記載の方法。 17.薬学的組成物の製造方法であって: (a)融合タンパク質をコードするDNAを宿主細胞中で発現する工程であって、該 タンパク質は(i)毒素活性を有さず、かつボツリヌス毒素に対する保護免疫性 を誘導し得るポリペプチドと(ii)クロマトグラフィーカラムに結合するように 適合された精製部分との融合物である、工程、 (b)該宿主細胞から該融合タンパク質を含む抽出物を得る工程、 (c)クロマトグラフィーカラムを用いて該融合タンパク質を精製する工程、お よび (d)該精製された融合タンパク質を薬学的組成物に組み込む工程 を包含する、方法。 18.前記精製部分がアフィニティークロマトグラフィーカラムに結合する、請 求項17に記載の方法。 19.薬学的組成物であって: (a)融合タンパク質であって、該タンパク質が(i)毒素活性を有さず、かつボ ツリヌス毒素に対する保護免疫性を誘導し得るポリペプチドと(ii)クロマトグ ラフィーカラムに結合するように適合されたポリペプチドとの融合物である融合 タンパク質であり、および (b)薬学的に受容可能なキャリア を含む、薬学的組成物。 20.前記融合タンパク質が請求項1〜6のいずれかに記載のポリペプチドを含 む、請求項19に記載の薬学的組成物。 21.前記融合タンパク質が、アフィニティークロマトグラフィーカラムに結合 するように適合されたポリペプチドを含む、請求項19または20に記載の薬学 的組成物。 22.請求項12に記載のワクチンを哺乳動物に投与する工程を包含する、ボツ リヌス毒素に対して該哺乳動物をワクチン接種する方法。 23.請求項19〜21のいずれかに記載の薬学的組成物を哺乳動物に投与する 工程を包含する、ボツリヌス毒素に対して該哺乳動物をワクチン接種する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9511909.5A GB9511909D0 (en) | 1995-06-12 | 1995-06-12 | Vaccine |
GB9511909.5 | 1995-06-12 | ||
PCT/GB1996/001409 WO1996041881A1 (en) | 1995-06-12 | 1996-06-12 | Type f botulinum toxin and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11507827A true JPH11507827A (ja) | 1999-07-13 |
JP4005633B2 JP4005633B2 (ja) | 2007-11-07 |
Family
ID=10775930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50279897A Expired - Fee Related JP4005633B2 (ja) | 1995-06-12 | 1996-06-12 | F型ボツリヌス毒素およびその用途 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7041792B2 (ja) |
EP (1) | EP0833919B1 (ja) |
JP (1) | JP4005633B2 (ja) |
AT (1) | ATE276366T1 (ja) |
AU (1) | AU705944B2 (ja) |
CA (1) | CA2224444C (ja) |
DE (1) | DE69633389T2 (ja) |
DK (1) | DK0833919T3 (ja) |
ES (1) | ES2224171T3 (ja) |
GB (1) | GB9511909D0 (ja) |
PT (1) | PT833919E (ja) |
WO (1) | WO1996041881A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004512004A (ja) * | 1999-05-12 | 2004-04-22 | ユナイテッド ステイツ アーミー メディカル リサーチ アンド マテリエル シーエムディー | ボツリヌス神経毒に対する組換えワクチン |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
DE19735105A1 (de) * | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
WO2000005252A1 (en) * | 1998-07-22 | 2000-02-03 | Agricultural Research Council | Vaccine comprising a non-toxic immunogenic derivative of clostridium botulinum type d neurotoxin |
US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
GB0525213D0 (en) * | 2005-12-12 | 2006-01-18 | Secr Defence | Vaccine |
EP2907504B1 (en) | 2011-02-08 | 2017-06-28 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
KR102175159B1 (ko) * | 2018-12-28 | 2020-11-05 | 대한민국 | 재조합 벡터, 형질전환 대장균, 보툴리눔 d/c형 중쇄 c말단 유래의 재조합 단백질을 포함하는 백신 조성물 및 키트 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
CA2141427C (en) * | 1992-07-31 | 2008-07-22 | Mohammed Anjam Khan | Expression of recombinant fusion proteins in attenuated bacteria |
GB9305919D0 (en) * | 1993-03-22 | 1993-05-12 | Health Lab Service Board | Botulinum toxin polypeptides and their use as vaccines |
-
1995
- 1995-06-12 GB GBGB9511909.5A patent/GB9511909D0/en active Pending
-
1996
- 1996-06-12 DK DK96917600T patent/DK0833919T3/da active
- 1996-06-12 AT AT96917600T patent/ATE276366T1/de active
- 1996-06-12 WO PCT/GB1996/001409 patent/WO1996041881A1/en active IP Right Grant
- 1996-06-12 EP EP96917600A patent/EP0833919B1/en not_active Expired - Lifetime
- 1996-06-12 JP JP50279897A patent/JP4005633B2/ja not_active Expired - Fee Related
- 1996-06-12 CA CA2224444A patent/CA2224444C/en not_active Expired - Fee Related
- 1996-06-12 DE DE69633389T patent/DE69633389T2/de not_active Expired - Lifetime
- 1996-06-12 PT PT96917600T patent/PT833919E/pt unknown
- 1996-06-12 US US08/981,087 patent/US7041792B2/en not_active Expired - Fee Related
- 1996-06-12 ES ES96917600T patent/ES2224171T3/es not_active Expired - Lifetime
- 1996-06-12 AU AU60121/96A patent/AU705944B2/en not_active Ceased
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004512004A (ja) * | 1999-05-12 | 2004-04-22 | ユナイテッド ステイツ アーミー メディカル リサーチ アンド マテリエル シーエムディー | ボツリヌス神経毒に対する組換えワクチン |
Also Published As
Publication number | Publication date |
---|---|
CA2224444A1 (en) | 1996-12-27 |
US20020081304A1 (en) | 2002-06-27 |
ATE276366T1 (de) | 2004-10-15 |
AU6012196A (en) | 1997-01-09 |
ES2224171T3 (es) | 2005-03-01 |
DE69633389D1 (de) | 2004-10-21 |
JP4005633B2 (ja) | 2007-11-07 |
AU705944B2 (en) | 1999-06-03 |
DK0833919T3 (da) | 2005-01-17 |
PT833919E (pt) | 2005-01-31 |
US7041792B2 (en) | 2006-05-09 |
EP0833919A1 (en) | 1998-04-08 |
DE69633389T2 (de) | 2005-10-27 |
EP0833919B1 (en) | 2004-09-15 |
CA2224444C (en) | 2010-02-16 |
WO1996041881A1 (en) | 1996-12-27 |
GB9511909D0 (en) | 1995-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0939818B1 (en) | Recombinant toxin fragments | |
AU2007201553B8 (en) | Expression system | |
AU708856B2 (en) | Peptide fragment of the respiratory syncytial virus protein g, immunogenic agent, pharmaceutical composition containing it and preparation process | |
RU2412253C2 (ru) | Рекомбинантная экспрессия белков в двухцепочечной форме с дисульфидным мостиком | |
JP2981286B2 (ja) | 破傷風トキシンフラグメントcの発現 | |
JP3072345B1 (ja) | 豚丹毒菌の組換えサブユニットワクチン | |
JPH11507827A (ja) | F型ボツリヌス毒素およびその用途 | |
CA2371279A1 (en) | Recombinant vaccine against botulinum neurotoxin | |
CA2121121C (en) | Preparation of recombinant borrelia proteins | |
US6287566B1 (en) | Protective peptides neurotoxin of C. botulinum | |
Wang et al. | Preparation of a peptide vaccine against GnRH by a bioprocess system based on asparaginase | |
US20030185850A1 (en) | Protective peptides neurotoxin of C. botulinum | |
Sakurai et al. | New evidence that the Tyr-157 and Tyr-159 residues of staphylococcal exfoliative toxin B are essential for its toxicity | |
KR101991577B1 (ko) | 다수의 에피토프로 구성된 재조합 항원 단백질 및 이의 제조방법 | |
WO2005034841A2 (en) | Anthrax vaccine | |
JP4273250B6 (ja) | 組換え毒素フラグメント | |
WO1998009648A9 (en) | NON-IgA Fc BINDING FORMS OF THE GROUP B STREPTOCOCCAL BETA ANTIGENS | |
KR20000068496A (ko) | B군 스트렙토코커스 베타 항원의 비-IgA Fc 결합형 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20040324 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070619 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070824 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100831 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100831 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100831 Year of fee payment: 3 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100831 Year of fee payment: 3 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110831 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110831 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120831 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130831 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |